Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01634126 · ClinicalTrials.gov registry record · Early Phase 1
Maximizing Yield of the Fecal Immunochemical Test for Colorectal Cancer Screening
A Early Phase 1 study, sponsored by Kaiser Permanente.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 2,761
- Enrollment target
NCT01634126: Completed Early Phase 1 study, sponsored by Kaiser Permanente.
NCT01634126 is a Early Phase 1 study that has completed, run by Kaiser Permanente. The registered enrollment target is 2,761 participants, above the 52-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (5210% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01634126, a Early Phase 1 study, has completed, sponsored by Kaiser Permanente.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 2,761 participants
- Enrollment target
Study Summary
Colorectal cancer (CRC) is a leading cause of cancer death in the United States. Screening for CRC reduces CRC mortality, yet rates of screening in the United States remain low. Fecal occult blood testing (FOBT) has an established positive balance of benefit and risk, is the least expensive, and is the preferred method for nearly half of patients. A newer fecal screening test, the fecal immunochemical test (FIT), offers significant improvements over the FOBT. It is easier to use and is more sensitive at detecting both CRC and precancerous adenomas than the FOBT. The OC-Micro FIT is of particular interest because it is highly sensitive and specific and it is the only FIT test approved in the US that can be processed in an automated manner. Thus, the OC-Micro is an optimal method for use in mass screening programs to improve community CRC-screening rates. However, prior studies of OC-Micro suffer from several limitations: they were conducted in populations not optimal for assessing screening performance in average risk patients in the U.S. and the studies did not clearly establish optimal number of samples required and cut-points for test positivity. Therefore, the overall goal of MY-FIT is to capitalize on the highly integrated and extensive electronic medical record system of the study site to collect two separate sets of data that, when synthesized, will provide a thorough picture of the comparative patient adherence to, sensitivity, specificity, and costs of different protocols for using the OC-Micro FIT. Specifically, among KPNW members aged 50-75 who are at average risk for colorectal cancer (CRC) and who are due for CRC screening (n=78,000), the investigators propose to: 1. Compare the sensitivity, specificity, positive predictive value, and negative predictive value for colorectal cancer and advanced adenoma (advanced neoplasia) between a single-sample FIT (1-FIT) and a two-sample FIT (2-FIT) using varying cut points for a positive test (n=2100). 2. Compare p
Primary Outcome
Among KPNW members aged 50-75 who are at average risk for colorectal cancer (CRC) and who are due for CRC screening, we propose to compare patient adherence to completion of a 1-FIT versus a 1-2 FIT protocol.
Interventions
- BEHAVIORAL 1 FIT kit
- BEHAVIORAL 2 FIT kit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,761 participants |
| Start Date | 2012-08 |
| Est. Completion | 2016-04 |
| Phase | Early Phase 1 |
What the finished NCT01634126 record still lists
NCT01634126 is an interventional study that assigns participants to a tested intervention. Its 2,761 participants enrollment target places it among the larger protocols in the corpus, above the 52-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (5210% higher).
The record links to 0 conditions, and to 2 interventions - of which 1 FIT kit is the first listed.
NCT01634126 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01634126 about?
NCT01634126 is a clinical study titled "Maximizing Yield of the Fecal Immunochemical Test for Colorectal Cancer Screening". Colorectal cancer (CRC) is a leading cause of cancer death in the United States. Screening for CRC reduces CRC mortality, yet rates of screening in the United States remain low. Fecal occult blood testing (FOBT) has an established positive balance of benefit and risk, is the least expensive, and is ...
What is the current status of trial NCT01634126?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 2,761 participants. The study started on 2012-08. Estimated completion is 2016-04.
What interventions are being tested in trial NCT01634126?
The interventions under investigation include: 1 FIT kit (BEHAVIORAL), 2 FIT kit (BEHAVIORAL).
Who is sponsoring clinical trial NCT01634126?
This trial is sponsored by Kaiser Permanente, which has 294 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01634126's enrollment target sits among peer trials
2,761 4th of 2000 higher than 1,997 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05443737 · 2,800 participants · Phase 3
Evaluation of a Telehealth Oncofertility Care Intervention in Adolescent and Young Adult Cancer Patients
- NCT05899439 · 2,800 participants
Immune Function and the Progression to T1D
- NCT06089109 · 2,800 participants · NA
Creating VIP Corps to Reduce Maternal Deaths
- NCT06345339 · 2,800 participants · Phase 2
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia